Q2 FY2026 EarningsQ2 FY2026 results showed a narrower-than-expected loss, with GAAP EPS of -$0.11 beating consensus of -$0.125. The company announced a major corporate restructuring including a 60% workforce reduction to prioritize its efzofitimod program in ILD, which is expected to reduce annualized operating expenses by $13M starting in Q4. With $58.9M in cash, the runway is now extended into late 2028, although further Phase 3 development will still require additional capital.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: ATYR Pharma(ATYR) the EBIT is -10.88 M (+46.43%), Beat estimate;the EPS is -0.11 (+50%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.01B46.43%
-0.01B40.57%
+0.00B5.86%
EPSExceed expectations
-0.1150.00%
-0.12543.18%
+0.01506.82%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf